PNPLA3 and metabolic dysfunction-associated steatotic liver disease: Resmetirom treatment resulted in a greater reduction in stellate cell activation and COL1A1 secretion in the PNPLA3 CC wild-type LAMPS compared to the GG variant LAMPS, demonstrating genotype-specific inhibition of MASLD progression